Fibrosis News
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are thrilled to receive this investment, which raises Third Pole Therapeutics’ series B financing and commitments to date to over $85M. I am ...
-
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
-
Simeox device is now available in Canada!
We are happy to announce that the #simeox device is now commercially available in Canada. Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, ...
By PhysioAssist
-
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results ...
By CohBar, Inc.
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release ...
By CohBar, Inc.
-
Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion. “It is with great pleasure that I ...
-
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
-
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
-
Inversago Pharma Awarded the Promising Health Biotech Company of the Year Gold Leaf Award at the BIONATION Conference in Ottawa
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the ?Promising Health Biotech Company of the Year' Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada. An initiative of BIOTECanada, the national industry association, coveted Gold ...
-
Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination
New York, NY and Providence, RI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that it has paid, and that Continental Stock Transfer & Trust Company has received, $1,050,000 from Aesther ...
-
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.
NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AHEA has filed with the U.S. Securities and Exchange Commission ("SEC") a preliminary proxy statement ...
-
Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program. Inversago scientists identified Diabetic Kidney Disease as the most ...
-
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital
NEW YORK and PROVIDENCE, R.I., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther” or the “Company”), a special purpose acquisition company (SPAC) has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company. The combined company will work to accelerate ...
-
Inversago Pharma presents data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), currently held in Barcelona, Spain and online. These data show that Inversago’s INV-101 (zevaquenabant), a small molecule, peripherally-acting CB1 ...
-
Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ
Ocean Biomedical’s innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets from research universities and medical centers. Ocean Biomedical’s initial core portfolios in oncology, fibrosis, and infectious diseases – all based on new target discoveries enabling first-in-class drug and vaccine ...
-
Inversago Pharma to present preclinical data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), to be held in Barcelona, Spain and online. Abstract: “INV-101, a cannabinoid receptor-1 inverse agonist, reduces fibrosis in a bleomycin mouse model ...
-
Inversago Pharma to participate to BIO International Convention 2022 in San Diego, CA
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. François Ravenelle, PhD, Chief Executive Officer of Inversago; Glenn D. Crater, MD, Chief Medical Officer; and, ...
-
Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane
Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, ...
-
Alejandro Lucia, researcher at the European University and collaborator of Microviable Therapeutics, National Award for Research in Sports Medicine.
It is always a pleasure to work with prestigious researchers. Congratulations Alejandro Lucia! for the award received. A group of ten researchers from various institutions, including Alejandro Lucia, a researcher at the European University and a Microviable collaborator, have received the Cajastur Foundation National Research Award in Sports Medicine, convened by the University of Oviedo, for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you